Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MSD’s Anti-MRSA Drug Cubicin Filed for Pediatric Use
January 28, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- BioAge Gets US/Europe Rights for Shionogi’s COVID-19 Treatment
January 27, 2021
- Pfizer’s Methotrexate 1000 mg Hit by Stock-Out on Flaws at German Manufacturing Site
January 27, 2021
- Kenei to Fight Maruho’s Claim over Healmild Trademark to the End
January 27, 2021
- Mitsubishi Tanabe Snaps Up Worldwide Rights for Antibody Drug Candidate for Autoimmune Diseases
January 27, 2021
- Nippon Express’s 3rd Pharma Distribution Hub Launched in Toyama
January 27, 2021
- Chugai’s FoundationOne Approved as CDx for Larotrectinib in Japan
January 26, 2021
- Health Damages Linked to Kobayashi Kako Mix-Up Rise to 215
January 26, 2021
- Mitsubishi Tanabe Gets US Commercial Rights for Aquestive’s ALS Med
January 25, 2021
- Shipment Control Triggered for Bayer’s Stivarga on Overseas Delay
January 25, 2021
- Chugai, Taisho to Wind Up Edirol Sales Collaboration in April
January 25, 2021
- Maruho Seeks to Block Sales of Kenei’s Healmild, Claims Close Resemblance to Hirudoid
January 25, 2021
- Yescarta Approved in Japan as 2nd CAR-T Cell Therapy
January 22, 2021
- Kyowa Pharma Controlling Shipments of 4 Generics on Recalls, COVID-19
January 22, 2021
- Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
- Taisho Kicks Off Japan PIII for Lusefi in Pediatric Type 2 Diabetes
January 22, 2021
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
- Pfizer Launching Joint Research Aimed at Broadening Use of Medical Big Data
January 21, 2021
- Enhertu Approved for Breast Cancer in Europe: Daiichi Sankyo/AZ
January 21, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…